BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems (DCTH)Delcath SystemsCompany update

QUEENSBURY, N.Y. --(BUSINESS WIRE)--Apr. 6, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has

Open original release

Related news

DCTHDelcath Systems2026-05-07 11:00 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-05-12 12:00 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

IDYAIDEAYA Biosciences2026-07-17 13:00 EST

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REGNRegeneron Pharmaceuticals2026-05-28 20:00 EST

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

EXELExelixis2026-05-19 12:00 EST

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

RLAYRelay Therapeutics2026-05-19 10:00 EST

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

RVMDRevolution Medicines2026-05-06 22:00 EST

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

View all latest news

Delcath Systems

Delcath Systems is a medical device and specialty oncology company focused on liver-directed cancer treatment. Its platform is built around regional therapy delivery for difficult tumors.

Recent company news

DCTHDelcath Systems2026-05-26 20:01 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

DCTHDelcath Systems2026-05-12 12:00 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

DCTHDelcath Systems2026-05-07 12:00 EST

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-05-07 11:00 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-04-23 12:30 EST

Delcath Systems to Host First Quarter 2026 Earnings Call

Stock data

Close
11.94 USD
Market cap
363.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States